[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356046-105":59,"doc-detail-356046-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","relationship-between-bisphosphonate-use-and-risks-of-recurrence-and-mortality-among-hormone-receptor-positive-and-triple-negative-breast-cancer-patients","Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor-positive and triple-negative breast cancer patients","","Adjuvant bisphosphonates are used to reduce bone recurrence risk in breast cancer, yet evidence across molecular subtypes remains limited. In this population-based cohort study, pre- and post-diagnostic bisphosphonate use were evaluated for recurrence, second breast cancer events, all-cause mortality, and breast cancer–specific mortality using multivariable Cox models in hormone receptor–positive and triple-negative patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/relationship-between-bisphosphonate-use-and-risks-of-recurrence-and-mortality-among-hormone-receptor-positive-and-triple-negative-breast-cancer-patients/356046/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/relationship-between-bisphosphonate-use-and-risks-of-recurrence-and-mortality-among-hormone-receptor-positive-and-triple-negative-breast-cancer-patients/356046.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main focus regarding bisphosphonates?","Question",{"text":112,"@type":113},"The study evaluated how pre- and post-diagnostic bisphosphonate use relates to recurrence and mortality outcomes in hormone receptor–positive versus triple-negative breast cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were outcomes analyzed in this cohort study?",{"text":117,"@type":113},"Effects on recurrence, second breast cancer events, all-cause mortality, and breast cancer–specific mortality were assessed using multivariable-adjusted Cox proportional hazards models.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find for hormone receptor–positive patients who used bisphosphonates after diagnosis?",{"text":121,"@type":113},"Post-diagnostic bisphosphonate use for at least one year was associated with lower all-cause mortality and breast cancer–specific mortality compared with never users in hormone receptor–positive cases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356046,1790175797,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10. 1002/cncr.70562  \nORIGINAL ARTICLE  \nRelationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple-negative breast cancer patients  \nLiuye Huang MHS 1,2  | Linda S. Cook PhD3 | Mei-Tzu C. Tang PhD 1 | David R. Doody MS 1 | Ulrike Peters PhD1,2 | Wei Sun PhD1,4 |  \nJeroen R. Huyghe PhD 1 | Kathleen E. Malone PhD 1,2 | Christopher I. Li MD, PhD 1,2   \n1Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA  \n2Department of Epidemiology, University of Washington, Seattle, Washington, USA 3Department of Epidemiology, University of Colorado-Anschutz, Aurora, Colorado, USA 4Department of Biostatistics, University of Washington, Seattle, Washington, USA  \nCorrespondence  \nChristopher I. Li, Public Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.  \nEmail: [cili@fredhutch.org](cili@fredhutch.org)  \nFunding information  \nBreast Cancer Research Foundation, Grant/ Award Number: BCRF-24-193; National Cancer Institute, Grant/Award Numbers:  \n261201000029C, P50, CA148143  \nAbstract  \nBackground: Bisphosphonates (BPs) are routinely used as an adjuvant therapy for breast cancer to reduce the risk of bone recurrences given their anti-resorptive effects on bones and antitumor characteristics. However, there remains limited evidence regarding their utility across different subtypes.  \nMethods: In this population-based cohort study, the authors assessed the effects of pre-and post-diagnostic BP use on recurrence, any second breast cancer event, allcause mortality (ACM), and breast cancer–specific mortality (BCSM) using multivariable-adjusted Cox proportional hazards models among hormone receptor–positive (HR+) and triple-negative breast cancer (TNBC) participants. Results: This study enrolled 2260 HR+ and 1436 TNBC participants. The median age and follow-up time to death was 51 and 52 years old and 168.3 and 147 months in the two subtypes, respectively. Post-diagnostic BP use for at least 1 year was protective for ACM (hazard ratio [HR], 0. 67; 95% confidence interval [CI], 0.49–0. 93) and BCSM (HR, 0. 54; 95% CI, 0.33–0.89) compared to never users in HR+ cases. Among participants who initiated BP after diagnosis only, a lower point estimates on the clinical outcomes were observed across both subtypes, reaching statistical significance for BCSM (HR, 0.62; 95% CI, 0.39–0. 98) in HR+ cases. Among TNBC cases who continued BP use post-diagnosis, increased risks of recurrence (HR, 3.43; 95% CI, 1.67–7.07) and BCSM (HR, 2. 54; 95% CI, 1.24–5. 19) were observed.  \nConclusions: Although this study confirmed the protective effects of postdiagnostic BP use on risks of mortality among HR+ cases, further studies are required to prove the effects of post-diagnostic BP use among TNBC participants.  \nKEYWORDS  \nbisphosphonates, hormone receptor positive breast cancer, mortality, recurrence, triplenegative breast cancer  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2026;e70562.  \n[https://doi.org/10.1002/cncr.70562](https://doi.org/10.1002/cncr.70562)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 13  \nINTRODUCTION  \nBreast cancer is the most common cancer among women globally.1 Over 90% of breast cancers are nonmetastatic at the time of diagnosis, with the 5-year survival rate varying from 85% to 99% across different subtypes. However, after metastatic recurrence, the median overall survival for patients can decrease to as low as 10 months.2 Thus, identifying factors contributing to recurrence is critical to reducing breast cance","cbCaidQ3yIlwOb4u","https://ap.wps.com/l/cbCaidQ3yIlwOb4u","pdf",1547593,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the study’s main focus regarding bisphosphonates?\",\"answer\":\"The study evaluated how pre- and post-diagnostic bisphosphonate use relates to recurrence and mortality outcomes in hormone receptor–positive versus triple-negative breast cancer patients.\"},{\"question\":\"How were outcomes analyzed in this cohort study?\",\"answer\":\"Effects on recurrence, second breast cancer events, all-cause mortality, and breast cancer–specific mortality were assessed using multivariable-adjusted Cox proportional hazards models.\"},{\"question\":\"What did the study find for hormone receptor–positive patients who used bisphosphonates after diagnosis?\",\"answer\":\"Post-diagnostic bisphosphonate use for at least one year was associated with lower all-cause mortality and breast cancer–specific mortality compared with never users in hormone receptor–positive cases.\"}]","Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor-positive and triple-negative breast cancer patients | PDF",1790122967,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6beb64b5ca11a7efa82840ac575fa753.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04ac99e0e2791d9871a10e7c3629366a.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee6cad1c321860dfb7690cdde42a75d4.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d81e853409c7cf4dc17146839b59a793.webp",980,1287]